Advertisement

Sexualsteroide und die Karzinogenese des Mammakarzinoms

  • K. Krauß
Part of the Onkologie Aktuell book series (ONKAKTUELL)

Zusammenfassung

Epidemiologische Daten haben Dauer und Zeitraum der Einwirkung von Östrogenen auf das Brustdrüsengewebe mit der Entwicklung von Brustkrebs in Zusammenhang gebracht.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E (1994) Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 86:1076–82PubMedCrossRefGoogle Scholar
  2. Armstrong BK (1988) Oestrogen therapy after menopause -boon or bane? Med J Aust 148: 213–214PubMedGoogle Scholar
  3. Barrett JC (1993) Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 100: 9–12PubMedCrossRefGoogle Scholar
  4. Barrett JC, Tsutsui T (1996) Mechanisms of estrogen-associated carcinogenesis. In: Huff J, Boyd J, Barrett JC (eds): Cellular and molecular mechanisms of hormonal carcinogenesis: environmental influences. Wiley-Liss: 105–111Google Scholar
  5. Barrett JC, Wong A, McLachlan JA (1981) Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science 212 (4501): 1402–1404PubMedCrossRefGoogle Scholar
  6. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-proge-stin replacement (see comments). N Engl J Med 321 (5): 293–297PubMedCrossRefGoogle Scholar
  7. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS (1999) A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 59 (8): 1869–1876PubMedGoogle Scholar
  8. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L (1995) Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85:11–17PubMedCrossRefGoogle Scholar
  9. Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL, Creasman WT (1999) An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med 44 (4): 186–192PubMedGoogle Scholar
  10. Cavalieri EL, Stack DE, Devanesan PD et al. (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94 (20): 10937–10942PubMedCrossRefGoogle Scholar
  11. Cerhan JR, Kushi LH, Olson JE, Rich SS, Zheng W, Folsom AR, Sellers TA (2000) Twinship and risk of postmenopausal breast cancer. J Natl Cancer Inst 92 (3): 261–265PubMedCrossRefGoogle Scholar
  12. Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR (1999) Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCFR-7 and T-47D, and the hormone-independent MDA-MB-231 breast cancer cell lines. Anticancer Res 19 (1A): 269–275PubMedGoogle Scholar
  13. Clarke CL, Sutherland RL (1990) Progestin Regulation of Cellular Proliferation. Endocr Rev 11 (2): 96–125CrossRefGoogle Scholar
  14. Clarke CL, Sutherland RL (1993) Progestin Regulation of Cellular Proliferation: Update 1993. Endocr Rev 1 (1): 132–135Google Scholar
  15. Colditz GA, Egan KM, Stampfer MJ (1993) Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 168:1473–1480PubMedGoogle Scholar
  16. Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 332 (24): 1589–1593PubMedCrossRefGoogle Scholar
  17. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, [see comments] [published erratum appears in Lancet 1997 Nov 15; 350 (9089):1484]. Lancet 350 (9084): 1047–1059CrossRefGoogle Scholar
  18. Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347 (9017): 1713–1727CrossRefGoogle Scholar
  19. DiSaia PJ, Grosen EA, Odicino F, Cowan B, Pecorelli S, Wile AG, Creasman WT (1995) Replacement therapy for breast cancer survivors. A pilot study. Cancer 76 (10 Suppl):2075–2078CrossRefGoogle Scholar
  20. Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151: 67–72PubMedCrossRefGoogle Scholar
  21. Dupont WD, Page DL, Rogers LW, Parl FF (1989) Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 63:948–957PubMedCrossRefGoogle Scholar
  22. Eden JA, Wren BG (1996) Hormone replacement therapy after breast cancer: a review. Cancer Treat Rev 22 (5): 335–343PubMedCrossRefGoogle Scholar
  23. Ettinger B et al. (1999) Multiple Outcomes of Raloxifene Evaluation (MORE randomized trial). J Am Med Ass 281 (23): 2189–2197CrossRefGoogle Scholar
  24. Ewertz M (1988) Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42: 832–838PubMedCrossRefGoogle Scholar
  25. Folsom AR, Min PJ, Sellers TA, Hong C-P, Zheng W, Potter JD (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 85 (8): 1128–1132PubMedCrossRefGoogle Scholar
  26. Gajdos C, Tartter PI, Babinszki A (2000) Breast cancer diagnosed during hormone replacement therapy. Obstetrics and Gynecology 95 (4): 513–518PubMedCrossRefGoogle Scholar
  27. Gemeinsame Stellungnahme der Deutschen Menopausenge-sellschaft, der European Menopause and Andropause Society, der Deutschen Gesellschaft für Senologie, der Deutschen Krebsgesellschaft u. a. (2000) Unterscheiden sich Gestagene hinsichtlich ihres Risikopotentials? Frauenarzt 41 (6): 714–718Google Scholar
  28. Grady D, Rubin SM, Petitti DB et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117:1016–1037PubMedCrossRefGoogle Scholar
  29. Grodstein F, Stampfer MJ, Colditz GA (1997) Postmenopausal hormone therapy and mortality [see comments]. N Engl J Med 336 (25): 1769–1775PubMedCrossRefGoogle Scholar
  30. Han X, Liehr JG (1994) DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15 (5): 997–1000PubMedCrossRefGoogle Scholar
  31. Harris RE, Namboodiri KK, Farrar WB, Solano SM, Wynder EL (1996) Hormone replacement therapy and breast cancer risk. JAMA 275:1158, discussion 1159–1160Google Scholar
  32. Henderson BE, Paganini-Hill A, Ross RK (1991) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75–78PubMedCrossRefGoogle Scholar
  33. Hodgson AV, Ayala-Torres, S, Thompson, EB, Liehr JG (1998) Estrogen-induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis 19 (12): 2169–2172PubMedCrossRefGoogle Scholar
  34. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84 (12): 4559–4565PubMedCrossRefGoogle Scholar
  35. Hunt K, Vessey M, McPershon K (1990) Mortality in a cohort of long-term users of hormone replacement therapy: an update analysis. Br J Obstet Gynecol 97:1080–1086CrossRefGoogle Scholar
  36. Kandouz M Lombet A, Perrot JY et al. (1999) Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Molec Biol 69 (1–6): 463–471PubMedCrossRefGoogle Scholar
  37. Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG (1994) Effects of progestagens and Org OD14 in vitro and in vivo tumor models. J Steroid Biochem Molec Biol 49 (4–6): 311–318PubMedCrossRefGoogle Scholar
  38. Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT (1997) Should women be advised against pregnancy after breast-cancer treatment? Lancet 350 (9074): 319–322PubMedCrossRefGoogle Scholar
  39. Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H (2000) Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 6 (2): 512–518PubMedGoogle Scholar
  40. Lange CA, Richer JK, Horwitz KB (1999) Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13 (6): 829–836PubMedCrossRefGoogle Scholar
  41. LaVecchia C et al. (1995) Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 72: 244–248PubMedCrossRefGoogle Scholar
  42. Li JJ, Hou X, Banerjee SK, Liao DZ, Maggouta F, Norris JS, Li SA (1999) Overexpression and amplification of c-myc in the Syrian hamster kidney during estrogen carcinogenesis: a probable critical role in neoplastic transformation. Cancer Res 59 (10): 2340–2346PubMedGoogle Scholar
  43. Liehr JG (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21 (1): 40–54PubMedCrossRefGoogle Scholar
  44. Liehr JG, Avitts TA, Randerath E, Randerath K (1986a) Estrogen-induced endogenous DNA adduction: possible mechanism of hormonal cancer. Proc Natl Acad Sci USA 83 (14): 5301–5305PubMedCrossRefGoogle Scholar
  45. Liehr JG, Stancel GM, Chorich LP, Bousfield GR, Ulubelen AA (1986b) Hormonal carcinogenesis: separation of estrogenicity from carcinogenicity. Chem Biol Interact 59 (2): 173–184PubMedCrossRefGoogle Scholar
  46. Liehr JG, Ricci MJ (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 93 (8): 3294–3296PubMedCrossRefGoogle Scholar
  47. Longacre TA, Bartow SA (1986) A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Patholio (6): 382–393Google Scholar
  48. Magnusson C, Baron JA, Correia, N, Bergstrom R, Adami HO Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81 (3): 339–344PubMedCrossRefGoogle Scholar
  49. Newcomb PA, Longnecker MP, Storer BE (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142: 788–795PubMedGoogle Scholar
  50. O’Neill JS, Elton RA, Miller WR (1988) Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J Clin Res Ed 296 (6624): 741–743PubMedCrossRefGoogle Scholar
  51. Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51 (3): 227–238PubMedCrossRefGoogle Scholar
  52. Osborne CK, Bradlow HL, Wong GY, Telang NT (1993) Upregulation of estradiol C16 alpha-hydroxilation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 85 (23): 1917–1920PubMedCrossRefGoogle Scholar
  53. Persson I, Yuen J, Bergvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy — long-term follow-up of a Swedish cohort. Int J Cancer 67:327–332PubMedCrossRefGoogle Scholar
  54. Potischman N, Troisi R (1999) In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 10 (6): 561–573PubMedCrossRefGoogle Scholar
  55. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50:7415–7421PubMedGoogle Scholar
  56. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz, KB (1998) Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 273 (47): 31317–31326PubMedCrossRefGoogle Scholar
  57. Rosenberg L, Palmer JR, Rao RS et al. (1996) Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 143 (1): 25–37PubMedCrossRefGoogle Scholar
  58. Ross RK, Paganini Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92 (4): 328–332PubMedCrossRefGoogle Scholar
  59. Russo J, Russo IH (1995) The etiopathogenesis of breast cancer prevention. Cancer Lett 90 (1): 81–89PubMedCrossRefGoogle Scholar
  60. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA — Journal of the American Medical Association 283 (4): 485–491CrossRefGoogle Scholar
  61. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Brad-low HL, Fishman L (1982) Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci 79 (9): 3047–3051PubMedCrossRefGoogle Scholar
  62. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R (1992) Menopausal hormone replacement therapy and breast cancer: a metaanalysis. Obstet Gynecol 79: 286–294PubMedGoogle Scholar
  63. Simpson ER, Merrill JC, Hollub AJ, Graham-Lorence S, Mendelson CR (1989) Regulation of estrogen biosynthesis by human adipose cells. Endocr Rev 10 (2): 136–148PubMedCrossRefGoogle Scholar
  64. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274:137–142PubMedCrossRefGoogle Scholar
  65. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL (1991) A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265 (15): 1985–1990PubMedCrossRefGoogle Scholar
  66. Tsutsui T, Suzuki N, Fukuda S, Sato M, Maizumi H, McLachlan JA, Barrett JC (1987) 17beta-Estradiol-induced cell transformation and aneuploidy of Syrian hamster embryo cells in culture. Carcinogenesis 8 (11): 1715–1719PubMedCrossRefGoogle Scholar
  67. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC (1999) Urinary 2-hydroxyestro-ne/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91 (12): 1067–1072PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • K. Krauß

There are no affiliations available

Personalised recommendations